Swedish Orphan Biovitrum appoints president and ceo

Geoffrey McDonough takes the role, joining the firm from Genzyme

Geoffrey McDonough, currently Genzyme’s president of Europe, Middle East and Africa (EMEA), will move Swedish Orphan Biovitrum (Sobi) as president and ceo on 15 August. He will succeed Kennet Rooth, who has been acting ceo since the beginning of the year.

McDonough has held several leading positions within Genzyme in the US since 2002, beginning his career with the firm in corporate development.

‘Geoff is well-recognised for his solid and broad commercial and clinical expertise and for his background in the orphan drug and niche speciality market,’ said Bo Jesper Hansen, chairman of Sobi.

‘He will lead Sobi toward our vision of becoming the leading niche speciality pharmaceutical company in Europe.’

You may also like

Research & Development
Sobi Orfadin capsules approved in Saudi Arabia

Sobi Orfadin capsules approved in Saudi Arabia

Swedish Orphan Biovitrum's orfadin capsules approved in the Kingdom of Saudi Arabia for the treatment of hereditary tyrosinemia type 1
Manufacturing

Sobi signs manufacturing agreements with Pfizer

Sobi is dedicated to developing and delivering innovative therapies for rare diseases
Pharmaceutical
CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta adds Tempus to companion diagnostic commercialisation network

CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
Packaging
Designing the future of pharma packaging – in Europe

Designing the future of pharma packaging – in Europe

Are you thinking about sustainable pharmaceutical packaging? ACG is committed to advancing sustainability in pharmaceutical packaging
Pharmaceutical
Reconstitutable powder filling system for global MedTech client

Reconstitutable powder filling system for global MedTech client

3P innovation's custom automation expertise enables customers to advance product and process innovation across diverse industries
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
Formulation freedom in clinical development: Why Fill2Weight matters

Formulation freedom in clinical development: Why Fill2Weight matters

As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Subscribe now